DAM
TCRT icon

Deltec Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Deltec Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-77
Closed -$65K – 187
2016
Q3 		$65K Hold
77
– – 0.01% 153
2016
Q2 		$63K Hold
77
– – 0.02% 145
2016
Q1 		$85K Buy
+77
New +$78.8K 0.02% 136
2015
Q1 		– Sell
-67
Closed -$51K – 157
2014
Q4 		$51K Buy
+67
New +$35.6K 0.01% 134

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deltec Asset Management's TCRT Position: Q4 2016 in Review

Deltec Asset Management sold out of Alaunos Therapeutics (TCRT) in Q4 2016, closing a stake of 77 shares — an estimated $65K sold.

Deltec Asset Management first reported a position in TCRT in Q4 2014 and held it in 4 quarters. The position peaked at $85K in Q1 2016. 136 funds tracked by Wall St. Rank hold TCRT as of Q4 2016.

  • Deltec Asset Management reported no remaining Alaunos Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Deltec Asset Management sold 77 Alaunos Therapeutics shares in Q4 2016, an estimated $65K.
  • Deltec Asset Management first reported a position in Alaunos Therapeutics in Q4 2014 and held it in 4 quarters.
  • Deltec Asset Management's Alaunos Therapeutics position peaked at $85K in Q1 2016.
  • 136 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2016.

Based on Deltec Asset Management's 13F filing for Q4 2016, filed 20 Jan 2017.